Fig. 3

Crude polysaccharide (CDDP) depreciate hyperglycemia and 2-h postprandial blood glucose (PBG-2 h) in STZ-induced T1DM mice. A Fasting blood glucose levels (mg/dL) in mice were measured at 0, 1, 2, 3 and 4 weeks during oral dosing of CDDP treatment. Model group showed an elevated levels of fasting blood glucose when compared to control group. Mice receiving CDDP doses and metformin via oral route had significantly reduced the elevated fasting blood glucose levels in comparison with model group. B Oral administration of 2.0 g/kg body weight of glucose to all overnight fasted mice. Measurement of blood glucose (mg/dL) was done at 0, 30, 60, 90 and 120 min. C AUC (mg/dL) was calculated by the formula. Data were represented as Means ± SEM (n = 10), evaluated by one-way ANOVA by Tukey’s Multiple Comparison Test. Control group (normal healthy control), model group (STZ-induced T1DM), metformin group (200 mg/kg body weight), DDP-Low: low dose of CDDP (200 mg/kg body weight), DDP-Med: medium dose of CDDP (400 mg/kg body weight) and DDP-High: high dose of CDDP (600 mg/kg body weight). # p < 0.05, ## p < 0.01 ### p < 0.001 and #### p < 0.0001, model group compared with control group * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001, CDDP and metformin treatment groups compared with model group